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WE investigated the effects of specific inhibitors
of cAMP-dependent protein kinase (PKA) and
cGMP-dependent protein kinase (PKG) on the
inhibitory activity of phosphodiesterase (PDE)
type 4 inhibitors and of the cell permeable
analogue of cAMP, db-cAMP on LPS-induced TNF-
release from human mononuclear cells. Incuba-
tion from 30 min of mononuclear cells with db-
cAMP (10-5 to 10-3M), rolipram (10-9M to
10-5 M) or Ro 20-1724 (10-9 M to 10-5 M) signifi-
cantly inhibited LPS-induced TNF- release. When
mononuclear cells were preincubated for 30 min
with the selective PKA inhibitor, H89 (10-4 M),
but not with the selective PKG inhibitor, Rp-8-
pCPT-cGMPs (10-4 M), a significant reduction of
the inhibitory effect of db-cAMP was noted. Thirty
min incubation of mononuclear cells with Rp-8-
pCPT-cGMPs induced a significant reduction of
the inhibitory activities of both rolipram and Ro
20-1724 (10-9 to 10-5 M) on LPS-induced TNF-
release, whereas H89 elicited a moderate, but
significant inhibition. The present data indicate
that db-cAMP inhibits TNF-z release from human
mononuclear cells through a PKA-dependent
mechanism. In contrast, PDE 4 inhibitors elicit
their in vitro anti-inflammatory activities via a
PKG-dependent rather than PKA-dependent acti-
vation.
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Introduction
The nucleotides cyclic 3’,5’adenosine mono-
phosphate (cAMP) and cyclic 3’,5’guanosine
monophosphate (cGMP) are important second
messengers. Indeed, increased intracellular
levels of cAMP or cGMP in both respiratory
smooth muscle and inflammatory cells result in
bronchodilatation, reduction of inflammation
12 and immunomodulatory activities.’ The intra-
cellular concentration of cyclic nucleotides is
mainly determined by intracellular breakdown
of cyclic nucleotide by phosphodiesterases
(PDEs). PDEs are a family of enzymes which
hydrolyse the 3’-ribose phosphate bond of the
naturally occurring second messenger nucleo-
tide 3’,5’-cyclic monophosphate to form the
biologically inert 5’-nucleotide monophosphate.
PDEs are at present divided into at least seven
families each with distinct substrate specificities
and regulatory characteristics.3’4 PDE 3 and PDE
4 are specifically responsible for cAMP hydro-
lysis, whilst PDE 5 is cGMP specific.
The physiological actions of cAMP and cGMP
are claimed to be mediated by cAMP-dependent
protein kinase (PKA) and cGMP-dependent
protein kinase (PKG), respectively.
5 This phe-
nomenon has been observed in many tissues,
where the activation state of PKA or PKG is
usually associated with the elevation of its
corresponding cyclic nucleotide, cAMP or
cGMP.5, However, partly because of a lack of
absolute specificity of either enzyme and of the
relatively high level of cAMP or cGMP in certain
tissues, it is also possible that either cyclic
nucleotide can cross-activate the other kinase.7
It has been previously demonstrated that the
PDE 4 inhibitors, rolipram and Ro 20-1724,
markedly reduced mononuclear cell activation
such as inhibition of fMLP-induced arachidonate
release and LPS-induced TNF- release from
human peripheral blood mononuclear cells.
8-11
Whether or not increase in intracellular cAMP is
involved in the anti-inflammatory activities of
PDE 4 inhibitors may be further clarified. In
order to evaluate the respective contribution of
the activation of protein kinases, we analysed
the effects of specific inhibitors of PKA and
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PKG on the inhibitory activities of PDE 4
inhibitors, rolipram and Ro 20-1724 and the cell
permeable analogue of cyclic AMP, db-cAMP on
TNF-z release from human monocytes.
Methods
Materials
The following agents and drugs were used:
Ficoll-Hypaque (Pharmacia, Upsala, Sweden),
phosphate buffered saline without Ca2+/Mg2+
(PBS), RPMI 1640, glutamine, penicillin and
streptomycin (Gibco, Cergy-Pontoise, France),
fetal calf serum (Flow Laboratories, Irvine, UK),
bovine serum albumin (BSA), lipopolysacchar-
ide (LPS) from Escherichia coli 055:B5, di-
methylsulphoxide (DMSO), dibutyryl cyclic
AMP (db-cAMP) (Sigma, St Louis, MO, USA), Ro
20-1724 (RBI, Natick, MA, USA), H89 (Calbio-
chem, San Diego, USA), Rp-8-pCPT-cGMPs
(BIOLOG Life Science Institute, Bremen, Ger-
many). Rolipram was synthetized at the Institut
de Recherche Jouveinal (Fresnes, France).
Preparation of human mononuclear
cells
Mononuclear cells were isolated from fresh
buffy coats obtained from healthy donors by
density gradient centrifugation on Ficoll-Hy-
paque as previously described,s Cells (1.5
106cells/ml) were seeded in 24-well Petri
dishes and cultured for 12 h (FALCON, Franklin
Lakes, NJ, USA) in RPMI-FCS (10%) at 37C in a
5% CO2 and 95% humidity atmosphere with or
without the indicated stimuli.
to 10-5 M) or Ro 20-1724 (10-9 to 10-5 M). All
drugs, were dissolved in RPMI supplemented
with 0.2% free fatty acid BSA with the exception
of PDE inhibitors which were dissolved in
dimethylsulphoxide (DMSO, Sigma, 0.1%, final
concentration). Vehicle controls were included
in the experimental design.
Data analysis
Results are expressed as percentage of control
of TNF-ct S.E.M. of four to five experiments,
done in triplicate. Analysis for statistical signifi-
cance was done by paired Student t-test.
Results
Incubation of mononuclear cells with db-cAMP
(10-5 to 10-
M), rolipram (10-9 M to 10-5 M)
or Ro 20-1724 (10-9 M to 10-5 M) for 30 min
concentration-dependently inhibited LPS-in-
duced TNF-z release (Figs 1-3). Fig. 1 also
shows that in the presence of the selective PKA
inhibitor, H89 (10-4 M) for 30 min, a significant
reduction of the inhibitory effect of rib-cAMP
(lO-4M to lO-3M) was noted. In contrast,
preincubation of the cells with the selective
PKG inhibitor, Rp-8-cpt-cGMPs (10-4 M), failed
to significantly modify the inhibitory activity of
db-cAMP on LPS-induced TNF<z release (Fig. 1).
When mononuclear cells were preincubated
for 30min with H89 (10-4 M), a moderate
inhibition of the effect of PDE 4 inhibitors,
rolipram and Ro 20-1724 was observed and
100
TNF- production
After stimulation with LPS (10 g/ml), cell-free
supernatants were collected, centrifugated
(2000g) and stored frozen at -20C prior to
TNF-c determination. TNF-cz concentrations in
cell culture supematants were determined by
specific ELISA using a commercial kit (Genzyme
Corp., Cambridge, MA, USA). Sensitivity of the
assay was 1 pg/ml. The absorbance at 450 nm
was assessed with an ELISA reader (Dynatech,
Alexandria, VA, USA).
Drug treatment
Mononuclear cells were incubated for 30 min
with H89 (10-4 M) or Rp-8-pCPT-cGMPs
(10-4 M), then they were treated for 30 min
with db-cAMP (10-5 M to 10-3 M) or with one
of the selective PDE 4 inhibitors, rolipram (10-9
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FIG. 1. Effects of H89 (B, 10-4 M) or Rp-8-pCPT-cGMPs (0,
10-4M) on the inhibitory activity of db-cAMP (10-5 to
10-3 M) on LPS-induced TNF-(z release from human mono-
nuclear cells. Results are expressed as percentage of
control of TNF-x 4- S.E.M. of four to five experiments done
in triplicate. *p < 0.05, ***p < 0.001 compared with the
responses of mononuclear cells incubated with db-cAMP
alone (control: F-l).Phosphodiesterase 4 inhibitors andprotein kinase
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FIG. 2. Effects of H89 (I, 10-4 M) or Rp-8-pCPT-cGMPs (O,
10-4M) on the inhibitory activity of rolipram (10-9 to
10-5 M) on LPS-induced TNF- release from human mono-
nuclear cells. Results are as percentage of control of TNF-
4-S.E.M. of four to five experiments done in triplicate.
*p < 0.05, compared with the responses of mononuclear
cells incubated with rolipram alone (control: rq).
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FIG. 3. Effects of H89 (I, 10-4 M) or Rp-8-pCPT-cGMPs (O,
10-4 M) on the inhibitory activity of Ro 20-1724 (10-9 to
10-5 M) on LPS-induced TNF-( release from human mono-
nuclear cells. Results are as percentage of control of TNF-
(z 4- S.E.M. of four to five experiments done in triplicate.
*p < 0.05, compared with the responses of mononuclear
cells incubated with Ro 20-1724 alone (control: 1-1).
appeared significant for 10-5 M rolipram and Ro
20-1724 (p < 0.05) (Figs 2 and 3). Hence,
30 min incubation of mononuclear cells with
Rp-8-cpt-cGMPs (10-4 M) induced a significant
reduction of the inhibitory activities of both
rolipram and Ro 20-1724 (10-9 M to 10-5 M) on
LPS-induced TNF-z release (Figs 2 and 3).
Discussion
It has long been known that cAMP is an
important second messenger in a wide variety
of cell systems. In general, intracellular eleva-
tion of cAMP level is thought to inhibit the
function of inflammatory cells. Hence, adenylyl
cyclase stimulating agents or PDE inhibitors
markedly reduced LPS-induced TNF-cz produc-
tion from mononuclear cells in various experi-
mental conditions.9- Nevertheless, PDE inhi-
bitors induced only a small increase of cAMP
despite pronounced TNF-cz suppression in LPS-
stimulated PBMC.14 We previously demonstrated
that PDE 4 inhibitors dose-dependently reduced
the fMLP-induced arachidonate release from
mononuclear cells.
8 However, this effect is not
closely associated with a rise in intracellular
cAMP, even though a significant enhancement
of intracellular cAMP has been observed after
incubation of the cells with PDE 4 inhibitors
plus forskolin, an activator of adenylyl cyclase.
8
Compartmentalization is a possible reason for
low overall levels of cAMP with PDE inhibitors.
Moreover, we recently observed that the selec-
tive PKA inhibitor, H89 did not significantly
reduce the inhibitory activity of db-cAMP and
PDE 4 inhibitors of fMLP-induced arachidonate
release from human monocytes.
15 Therefore, we
investigated the possible interactions of PKA
and PKG inhibitors on the activity of PDE 4
inhibitors on LPS-induced TNF-cz release from
mononuclear cells.
The present research confirmed that the cell
permeable analogue of cAME db-cAMP and the
PDE 4 inhibitors, rolipram and Ro 20-1724
concentration-dependently inhibited the LPS-
induced TNF-cz release from mononuclear cells.
As expected, the present data also showed that
the selective PKA inhibitor H8916’17 reduced the
inhibition of TNF-z release from human mono-
cytes elicited by db-cAMP, whereas the selective
18 PKG inhibitor Rp-8-pCPT-cGMPs was not mark-
edly effective. These results suggest that PKA
activation is mainly involved in the mechanism
of action ofdb-cAMP in mononuclear cells.
Rp-8-pCPT-cGMPs significantly reduced the
inhibitory activities of the two PDE 4 inhibitors,
rolipram and Ro 20-1724, whereas H89 only
elicited moderate activities which was only
statistically significant at the highest concentra-
tion of PDE 4 inhibitors. Therefore, the present
data demonstrated a mechanism insensitive to
H89 and therefore independent of PKA for
rolipram and Ro 20-1724. Similar observations
have been recently reported, where cyclic AMP-
elevating agents and db-cAMP prolonged eosino-
phil survival by mechanisms insensitive to H89
and therefore PKA-independent.19 In contrast,
the results obtained with Rp-8-pCPT-cGMPs
suggest an involvement of PKG in the mechan-
ism of action of PDE 4 inhibitors.
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Until recently, it was accepted that cAMP and
cGMP activate their respective kinases with a
high degree of specificity. The validity of this
assumption has steadily declined over the past
decade and it now appears that there is
evidence for cross-activation of PKA and PKG
by adenyl and guanyl 3’:5’-cyclic nucleotides
(for review see Ref. 20). Moreover, their cyclic
nucleotide binding domains share a high degree
of amino acid sequence identity, since only a
single alanine-threonine difference between
their cAMP- and cGMP-binding domains partially
accounts for this specificity.721 Such a cross-
activation occurred in airway smooth muscle
cells where cAMP activates PKG with an EC50
of 80 nM, which is slightly different than the
cAMP ECs0 for PKA (30 nM).
22 Involvement of
PKG in cAMP mediated actions has been also
reported for the cardiovascular system. For
example, it has been reported that the increase
in cAMP content following treatment of bovine
coronary arteries with isoproterenol results in a
simultaneous activation of both PKA and PKG.23
Moreover, an important role for PKG in mediat-
ing the relaxant response to cAMP have been
noted in rat aortic smooth muscle cells in
culture.
24 Recently, Eckly and colleagues
25 re-
ported that PKG is involved in rolipram-induced
vascular relaxation of rat aorta. Since rolipram
only increased cAMP content, these data also
suggest a cross-activation of PKG by cAMP in
rat aorta.
In conclusion, we showed that db-cAMP
inhibits TNF-c release from human mono-
nuclear cells through a PKA-dependent mechan-
ism. Furthermore, the selective PKG inhibitor,
Rp-8-pCPT-cGMPs but not the selective PKA
inhibitor, H89 significantly reduced the inhibi-
tory activity of PDE 4 inhibitors on LPS-induced
TNF-c release from human mononuclear cells.
Therefore, these results suggest a PKA-indepen-
dent and a PKG-dependent mechanism for the
in vitro anti-inflammatory activity of PDE 4
inhibitors, which may be further clarified.
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